Loading...
•
Jun 30, 2023
Amedisys Q2 2023 Earnings Report
Amedisys reported a net loss attributable to Amedisys, Inc. of $80.3 million, which is inclusive of $125.5 million in costs associated with merger transactions, compared to net income attributable to Amedisys, Inc. of $29.6 million in 2022.
Key Takeaways
Amedisys, Inc. reported a decrease in net service revenue to $553.0 million compared to $557.9 million in 2022. The company experienced a net loss attributable to Amedisys, Inc. of $80.3 million, inclusive of merger-related costs, contrasting with a net income of $29.6 million in the previous year. Adjusted EBITDA was $74.6 million, slightly up from $74.4 million in 2022.
Net service revenue decreased by $4.9 million year-over-year to $553.0 million.
Net loss attributable to Amedisys, Inc. was $80.3 million, impacted by $125.5 million in merger transaction costs.
Adjusted EBITDA increased slightly to $74.6 million from $74.4 million in the prior year.
The company has suspended guidance on 2023 financial performance due to the pending merger with UnitedHealth Group Incorporated.
Forward Guidance
Amedisys has decided to suspend providing forward guidance on 2023 financial performance due to the pending merger with UnitedHealth Group Incorporated.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...